Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 16, 2018Current Pharmaceutical Design

The Role of Colchicine in Pericardial Syndromes

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does colchicine improve outcomes and prevent recurrences in patients with pericardial syndromes when added to conventional treatment?

Population

Patients with pericardial syndromes, including acute and recurrent pericarditis of viral, idiopathic, and…

Comparison

Colchicine added to conventional treatment vs Conventional treatment alone

Design

Review

Authors

GLGeorge LazarosMIMassimo ImazioABAntonio Brucato

Discussion

Loading...

Member takes

Overview

Colchicine merits consideration across pericarditis, CAD, AF, and HF; review extends evidence synthesis but leaves practice change to future trials.

Structured PICO

Does colchicine improve outcomes and prevent recurrences in patients with pericardial syndromes when added to conventional treatment?

P
Population
Patients with pericardial syndromes, including acute (first episode) and recurrent pericarditis of viral, idiopathic, and autoimmune origin, and those at risk for postpericardiotomy syndrome
I
Intervention
Colchicine added to conventional treatment
C
Comparator
Conventional treatment alone (implied from placebo-controlled trials)
O
Outcome
Treatment of acute and recurrent pericarditis and prevention of recurrences/postpericardiotomy syndrome

Colchicine is a safe and effective first-line therapy, added to conventional treatment, for the management of acute and recurrent pericarditis and the prevention of postpericardiotomy syndrome.

Cite This Study

Lazaros et al. (2018) studied this question.

synapsesocial.com/papers/6a715bf9ac440176ef2a0a90https://doi.org/10.2174/1381612824666180116101823
View Full Paper
Ask AI
Bookmark
Share